John McCall, PhD, is a medicinal chemist with extensive experience in pharmaceutical and biotechnology companies. His expertise includes medicinal biochemistry, steroidal chemistry, risk minimization, and strategic planning.
Dr. McCall is co-founder of ReveraGen BioPharma, where he currently serves as Chairman of the Board and Vice President of Chemistry. He also chairs a National Institute of Neurological Disorders and Stroke development team in the spinal muscular atrophy area and participates as a National Institutes of Health (NIH) study section member. Additionally, Dr. McCall consults, works with venture capital funds, and is a partner with the Upjohn Group. He began his career as a medicinal chemist with Upjohn and subsequently held leadership positions in chemistry and research for Pharmacia, Pharmacia Upjohn, and Pfizer. In the past, he has consulted through his privately owned PharMac firm, advising the NIH, academic, and pharmaceutical partners in the translational drug discovery and development areas. Dr. McCall’s board and scientific advisory board positions include UCB, CeeTox, Synergenics, Psychogenics, Avaant, Deciphera, Lycera, Michigan High Throughput Screening Center, Verseon, CINRG, Reaction Biology, Scripps, AdmetRx, and PharmOptima. He holds 54 U.S. patents and has over 60 peer-reviewed publications.
Dr. McCall received his doctorate degree from the University of Wisconsin-Madison and completed his post-doctorate work at Harvard.